Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

409 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.
Dietz-Fricke C, Degasperi E, Jachs M, Maasoumy B, Reiter FP, Geier A, Grottenthaler JM, Berg CP, Sprinzl K, Zeuzem S, Gödiker J, Schlevogt B, Herta T, Wiegand J, Soffredini R, Wedemeyer H, Deterding K, Reiberger T, Lampertico P. Dietz-Fricke C, et al. Among authors: lampertico p. Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847. Online ahead of print. Hepatology. 2024. PMID: 38478755
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L, Cotler SJ, Degasperi E, Anolli MP, Uceda Renteria SC, Sambarino D, Borghi M, Perbellini R, Facchetti F, Ceriotti F, Lampertico P, Dahari H. Shekhtman L, et al. Among authors: lampertico p. JHEP Rep. 2023 Nov 15;6(2):100966. doi: 10.1016/j.jhepr.2023.100966. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274491 Free PMC article.
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier RC, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P. Wedemeyer H, et al. Among authors: lampertico p. J Hepatol. 2024 May 9:S0168-8278(24)00333-7. doi: 10.1016/j.jhep.2024.05.001. Online ahead of print. J Hepatol. 2024. PMID: 38734383 Free article.
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
Di Cola S, D'Amico G, Caraceni P, Schepis F, Loredana S, Lampertico P, Toniutto P, Martini S, Maimone S, Colecchia A, Svegliati Barone G, Alessandria C, Aghemo A, Crocè SL, Adinolfi LE, Rendina M, Lapenna L, Pompili E, Zaccherini G, Saltini D, Iavarone M, Tosetti G, Martelletti C, Nassisi V, Ferrarese A, Giovo I, Masetti C, Pugliese N, Campigotto M, Nevola R, Merli M; EpatoSarco Group. Di Cola S, et al. Among authors: lampertico p. J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.05.020. Online ahead of print. J Hepatol. 2024. PMID: 38782120 Free article.
EASL Clinical Practice Guidelines: management of chronic hepatitis B.
European Association For The Study Of The Liver. European Association For The Study Of The Liver. J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29. J Hepatol. 2009. PMID: 19054588 Review. No abstract available.
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M; PegBeLiver Study Group. Lampertico P, et al. Gut. 2013 Feb;62(2):290-8. doi: 10.1136/gutjnl-2011-301430. Epub 2012 Aug 2. Gut. 2013. PMID: 22859496 Clinical Trial.
409 results